Language: BG BG
← Back to results
Recruiting Phase 2/3 NCT07112196

Visugromab in Cachexia International Trial

Phase 2/3 – combined trial
Conditions: Cancer-associated Cachexia

Sponsor: CatalYm GmbH

trial.available_in:
Overview
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.
Who can participate
Inclusion Criteria: * Weight loss * Advanced cancer Exclusion Criteria: * Participation in another interventional clinical trial, receipt of any investigational therapy or use of any investigational device within 4 weeks prior to screening and between screening and the first dose of investigational product
Interventions
Visugromab (CTL-002)
DRUG
Placebo
DRUG
Visugromab (CTL-002)
DRUG
Visugromab (CTL-002)
DRUG
Locations 7
Bulgaria (1)
Specialized Hospital for Active Treatment in Oncology
Haskovo
France (1)
Léon Bérard Center (Centre Léon Bérard)
Lyon
Norway (1)
Oslo University Hospital
Oslo
Spain (1)
University Hospital of A Coruña (Hospital Universitario de A Coruña)
A Coruña
Switzerland (2)
Cantonal Hospital St. Gallen (Kantonsspital St. Gallen)
Sankt Gallen
University Hospital of Zurich (Universitätsspital Zürich)
Zurich
United States (1)
Mid Florida Hematology and Oncology Centers
Orange City , Florida
Technical details
Status
Recruiting
Phase
Phase 2/3
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
16.04.2026
Completion date
01.12.2030
Registry ID
NCT07112196
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.